Predictors of HER2 FISH amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Maria Vittoria Dieci1, Elena Barbieri1, Stefania Bettelli², Federico Piacentini1, Guido Ficarra², Sara Balduzzi1, Massimo Dominici1, PierFranco Conte1, Valentina Guarneri1
1Department of Oncology, Hematology and Respiratory Diseases, and ²Department of Pathology, University Hospital, Modena, Italy
Herbst. Int J Radiat Oncol Biol Phys. 2004;59(suppl):21; Roskoski. Biochem Biophys Res Commun. 2004;319:1; Rowinsky. Annu Rev Med. 2004;55:433
Abnormal low immunohistochemistry score 2+ infiltrating breast cancer:
IHC Images by Kornstein, MD, Medical College of Virginia
As a consequence:
Mass. Proc Am Soc Clin Oncol. 2000; Shah, Hum Pathol 2010
To evaluate if routinely assessed pathologic parameters such as tumor grade, hormone receptor status and Ki67 are able to predict FISH results in patients with an equivocal IHC HER2 score 2+
ANTIBODY: Novocastra Laboratories, clone CB11 until June 2008 and Ventana, clone 4B5 from July 2008
PROBE: PathVysion HER-2 DNA Probe Kit (Vysis Inc., Downers Grove, IL)